Blood cyclosporine level soon after kidney transplantation is a major determinant of rejection: Insights from the mycophenolate steroid-sparing trial

Transplantation Proceedings

Volumn 37, Issue 5, 2005, Pages 2037-2040

  Gotti, E ^a   Perico, N ^a   Gaspari, F ^a   Cattaneo, D ^a   Lesti, M D ^a   Ruggenenti, P ^a   Segoloni, G ^a   Salvadori, M ^a   Rigotti, P ^a   Valente, U ^a   Donati, D ^a   Sandrini, S ^a   Federico, S ^a   Sparacino, V ^a   Mourad, G ^a   Bosmans, J L ^a   Dimitrov, B D ^a   Iordache, B E ^a   Remuzzi, G ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; T LYMPHOCYTE ACTIVATION;

ADRENAL CORTEX HORMONES; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BIOPSY; CLINICAL TRIALS; CREATININE; CYCLOSPORINE; DRUG MONITORING; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 21844432663     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.03.096     Document Type: Article

References (18)

1. D.W. Gjertson J.M. Cecka P.I. Terasaki 2000 UCLA Immunogenetics Center Los Angeles, Calif 467
2. D.M. Briscoe, M.H. Sayegh A rendezvous before rejection where do T cells meet transplant antigens? Nature Med 8 2002 220
3. P. Keown, D. Landsberg, P. Halloran A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients Transplantation 62 1996 1744
4. J.R. Beck, E.K. Schultz The use of relative operating characteristic (ROC) curves in test performance evaluation Arch Pathol Lab Med 110 1986 13
5. T. Leivestad, A.V. Reisaeter, I.B. Brekke The role of HLA matching in renal transplantation experience from one center Rev Immunogenet 1 1999 343
6. J.T. Joseph, D.B. Kingsmore, B.J. Junor The impact of acute rejection after cadaveric kidney transplantation Clin Transplant 15 2001 221
7. J. Grevel, M.S. Welsh, B.D. Kahan Cyclosporine monitoring in renal transplantation area under the curve monitoring is superior to trough-level monitoring Ther Drug Monit 11 1989 246
8. A. Perna, E. Gotti, E. De Bernardis A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity J Am Soc Nephrol 7 1996 786
9. A. Lindholm, B.D. Kahan Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation Clin Pharmacol Ther 54 1993 205
10. E. Cole, K. Midvedt, A. Johnston Recommendations for the implementation of Neoral C2 monitoring in clinical practice Transplantation 73 2002 S19
11. F.G. Lakkis, A. Arakelov, B.T. Konieczny Immunologic " ignorance" of vascularized organ transplants in the absence of secondary lymphoid tissue Nature Med 6 2000 686
12. R.L. Reinhardt, A. Khoruts, R. Merica Visualizing the generation of memory CD4 T cells in the whole body Nature 410 2001 101
13. + T cells and trigger acute rejection an alternative mechanism of allorecognition Nature Med 8 2002 233
14. J. Liu, J.D. Farmer Jr, W.S. Lane Calcineurin is a common target of cyclophillin-cyclosporin A and FKBP-FK506 complexes Cell 66 1991 807
15. R. Caruso, N. Perico, D. Cattaneo Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients Clin Chem 47 2001 1679
16. N. Perico, G. Remuzzi Prevention of transplant rejection. Current treatment guidelines and future developments Drugs 54 1997 533
17. H.W. Sollinger US Renal Transplant Mycophenolate Mofetil Study Group Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients Transplantation 50 1995 225
18. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation Transplantation 61 1996 1029